| First Author | Burg AR | Year | 2020 |
| Journal | J Immunol | Volume | 205 |
| Issue | 2 | Pages | 447-453 |
| PubMed ID | 32522837 | Mgi Jnum | J:291699 |
| Mgi Id | MGI:6445408 | Doi | 10.4049/jimmunol.1901412 |
| Citation | Burg AR, et al. (2020) Persistent Zika Virus Clinical Susceptibility despite Reduced Viral Burden in Mice with Expanded Virus-Specific CD8(+) T Cells Primed by Recombinant Listeria monocytogenes. J Immunol 205(2):447-453 |
| abstractText | Vaccines against Zika virus (ZIKV) infection that target CD8(+) T cells are of considerable interest because Abs may enhance infection susceptibility. However, whether CD8(+) T cells are protective or promote susceptibility to clinical infection symptoms remains uncertain. To more precisely investigate ZIKV-specific CD8(+) T cells in isolation, we engineered a Listeria monocytogenes-based vector to express a single MHC class I-restricted immune dominant peptide, E294-302, from ZIKV envelope protein. We show accumulation of activated ZIKV-specific CD8(+) T cells primed by recombinant L. monocytogenes is associated with reductions in circulating virus levels after ZIKV challenge in type I IFN receptor-deficient mice and wildtype mice administered neutralizing Abs against type I IFN receptor. Interestingly, susceptibility to ZIKV clinical infection including weight loss and mortality each persists and is neither significantly improved nor worsened compared with isogenic L. monocytogenes-primed control mice. These data demonstrating persistent ZIKV clinical susceptibility despite reduced viral burden in mice with expanded virus-specific CD8(+) T cells highlights the need for targeting other adaptive immune components in developing vaccines against ZIKV infection. |
